EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Cefepime Combined with Late-Generation β-Lactamase Inhibitors: Mechanisms of Action, In Vitro Activity, PK/PD Characteristics, Clinical Evidence and Resistance Mechanisms

Sara Comini, Matteo Boattini iD, Paolo Gaibani iD, Gabriele Bianco iD

Antibiotics · 03.03.2026 · 15 (3) · 263

DOI: 10.3390/antibiotics15030263 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Antibiotics, online erschienen am 03.03.2026. Verfasst von Sara Comini und 3 weiteren Autor:innen. Beteiligte Einrichtung: Operative Unit of Clinical Pathology, Carlo Urbani Hospital, 60035 Ancona, Italy. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 106 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cefepime combined with late-generation β-lactamase inhibitors—enmetazobactam, zidebactam, and taniborbactam—represents a promising strategy to treat multidrug-resistant Gram-negative infections. These combinations expand the therapeutic armamentarium beyond established β-lactam/β-lactamase inhibitor regimens, offering targeted activity against ESBL-, AmpC-, and carbapenemase-producing Enterobacterales, as well as multidrug-resistant Pseudomonas aeruginosa. In vitro studies highlight potent and broad activity, with mechanisms including β-lactamase inhibition and, in the case of zidebactam, dual β-lactam enhancement through PBP2 binding. Clinical evidence demonstrates efficacy in complicated urinary tract infections and suggests potential for treating extensively drug-resistant infections, including those unresponsive to conventional β-lactam/β-lactamase inhibitors. Emerging resistance mechanisms—such as PBP alterations, porin loss, efflux pump overexpression, and evolving KPC or NDM variants—underscore the need for ongoing surveillance and robust susceptibility testing. This review provides a comprehensive overview of the mechanisms of action, in vitro activity, pharmacokinetic/pharmacodynamic properties, clinical outcomes, and resistance patterns of these cefepime-based combinations. It also highlights future directions, including the establishment of clinical breakpoints, evaluation in severe infections, and exploration of combination strategies to counteract complex resistance. Overall, these agents exemplify a strategic evolution in β-lactam therapy, offering versatile options to reduce carbapenem reliance while maintaining high efficacy against multidrug-resistant Gram-negative pathogens.

Schlagwörter

Stichwörter der Autor:innen

KPCOXA-48-likecarbapenem sparingcefepime/enmetazobabtamcefepime/taniborbactamcefepime/zidebactammetallo-β-lactamasemulti-drug-resistancenovel β-lactamase inhibitorresistance mechanism

Autor:innen und Institutionen

  • Operative Unit of Clinical Pathology, Carlo Urbani Hospital, 60035 Ancona, Italy.
  • Microbiology and Virology Unit, University Hospital Città della Salute e della Scienza di Torino, 10126 Turin, Italy.
  • Department of Public Health and Paediatrics, University of Torino, 10126 Turin, Italy.
  • Lisbon Academic Medical Centre, 1000-001 Lisbon, Portugal.
  • Microbiology and Virology Unit, Department of Pathology, Azienda Ospedaliera Universitaria Integrata di Verona, 37121 Verona, Italy.
  • Department of Diagnostic and Public Health, Microbiology Section, University of Verona, 37121 Verona, Italy.

ORCID-Profile: Matteo Boattini, Paolo Gaibani, Gabriele Bianco

Zitieren

APA

Comini, S., Boattini, M., Gaibani, P., & Bianco, G. (2026). Cefepime Combined with Late-Generation β-Lactamase Inhibitors: Mechanisms of Action, In Vitro Activity, PK/PD Characteristics, Clinical Evidence and Resistance Mechanisms. Antibiotics, 15(3), 263. https://doi.org/10.3390/antibiotics15030263

Vancouver

Comini S, Boattini M, Gaibani P, Bianco G. Cefepime Combined with Late-Generation β-Lactamase Inhibitors: Mechanisms of Action, In Vitro Activity, PK/PD Characteristics, Clinical Evidence and Resistance Mechanisms. Antibiotics. 2026;15(3):263. doi:10.3390/antibiotics15030263

BibTeX
@article{Comini2026,
  author = {Comini, Sara and Boattini, Matteo and Gaibani, Paolo and Bianco, Gabriele},
  title = {Cefepime Combined with Late-Generation β-Lactamase Inhibitors: Mechanisms of Action, In Vitro Activity, PK/PD Characteristics, Clinical Evidence and Resistance Mechanisms},
  journal = {Antibiotics},
  year = {2026},
  volume = {15},
  number = {3},
  pages = {263},
  doi = {10.3390/antibiotics15030263}
}
Kostenlos starten →